---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-377059"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-08-31T21:18:23+00:00"
generated_at: "2026-08-31T21:20:09.908205+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kyntra Bio cuts royalty financing cap from $125M to $65M; pays $42.6M upfront

## Summary
- Max payments under royalty financing cut from $125M to $65M; $42.6M accelerated payment brings total paid to $50M, full return of investor capital.
- Remaining $15M cap paid from 50% of Astellas EVRENZO revenue (ex-Japan); after cap, Kyntra retains all royalties.
- FibroGen Europe bankruptcy settled for ~$0.1M vs $19.2M obligations; combined liability reduction ~$80M.
- Pro forma cash $53.1M as of June 30, 2026; cash runway into Q4 2027.

## SEC filing metadata
- accession: 0001193125-26-377059
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-08-31T21:18:23+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526377059/0001193125-26-377059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526377059/kynb-20260831.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-377059
- JSON: https://secwatch.observer/filing/0001193125-26-377059.json
- Plain text: https://secwatch.observer/filing/0001193125-26-377059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.